Questions

Answers

1. Which one of the following is not a pure beta (β) emitter?

A. yttrium-90

B. strontium-89

C. phosphorus-32

D. iodine-131

1. D, iodine-131

2. What is the predominant purpose of pretreatment with a nonradioactive antibody during dosimetry and therapy?

2. binding of antigen sinks (e.g., in the spleen)

3. What organ determines the dose limit for most radionuclide therapies?

3. bone marrow

4. Which portion of the antibody is responsible for cytotoxicity and human anti-mouse antibody (HAMA)?

4. Fc portion

5. Which of the following are true regarding HAMA?

A. It occurs in one-third of patients treated with murine antibodies.

B. It produces falsely elevated tumor markers.

C. Its titers spontaneously resolve in the majority of cases.

D. It alters biodistribution for future radionuclide therapies.

5. A, B, C, and D

6. __________ antigen, which is expressed in 90% of mature B-cells and not in progenitor stem cells, and which is not shed or internalized, is utilized as the target antigen for lymphoma therapy.

6. CD20

7. The therapeutic effect of radioactive labeled antibody versus a non-radio-labeled antibody in the treatment of lymphoma is due to beta (β) radiation resulting in __________ effect.

7. crossfire

8. True or false: ⁹⁰Y ibritumomab tiuxetan (Zevalin) and ¹³¹I tositumomab (Bexxar) are chimeric antibodies to CD20 antigen.

8. false

9. Contraindications for radionuclide therapy in lymphoma include the following:

A. external beam radiation involving 25% of the bone marrow

B. less than 15% cellular bone marrow

C. prior BMT or SCT

D. platelets less than 100k or ANC less than 1500 cells/mm³

Related posts:

Quality Control Cardiac Thyroid Gland and Endocrine System Gastrointestinal Lymphomas Musculoskeletal

Stay updated, free articles. Join our Telegram channel

Join

Full access? Get Clinical Tree